Endoscopic balloon dilation for treatment of sleeve gastrectomy stenosis: a systematic review and meta-analysis.
Gastric stenosis is a rare but potentially serious adverse event after sleeve gastrectomy. Despite current suboptimal treatments, endoscopic balloon dilatation (EBD) has emerged as a safe and efficacious approach. The purpose of this study is to assess the overall success of EBD for sleeve gastrectomy stenosis (SGS) as first-line therapy. MEDLINE, Embase, Web of Science, Google Scholar, and Cochrane Database were searched from inception to July 2018, whereas OPUS, LILACS, BVS, CINAHL were not searched. The primary outcome was defined as overall success rate of clinical resolution of SGS obstructive symptoms with EBD, expressed as pooled event rate and 95% confidence interval (95% CI). The secondary predefined outcomes include EBD success rates for SGS in proximal (cardia) location or mid-distal location (antrum/incisura), in early SGS (up to 3 months after LSG) and late SGS (3 months or longer after LSG), and success rate of cases requiring stents or salvage surgery. Eighteen studies encompassing 426 patients were analyzed. The average age and BMI were 41.7 and 40.1, respectively, and average number of dilations for all cases was 1.8 per person. Overall EBD success rate was 76% (95% CI, 0.67-0.86). EBD success rates were as follows: proximal SGS was 90% (95% CI, 63%-98%); distal SGS was 70% (95% CI, 47%-86%); early SGS within 3 months was 59% (95% CI, 34%-79%); and late SGS after 3 months was 61% (95% CI, 41%-78%). Seventeen percent of patients underwent secondary salvage surgery, with a success rate of 91% (95% CI, 80%-96%). EBS appears to be a safe and effective minimally invasive alternative to surgical revision and should be used as first-line therapy for SGS.